A Novel Approach to Prevent Surgical Diabetes in Chronic Pancreatitis Patients
预防慢性胰腺炎患者手术糖尿病的新方法
基本信息
- 批准号:8638118
- 负责人:
- 金额:$ 22.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-01-01 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAllogenicAllograftingAnimal ModelApoptosisAutologous TransplantationBiometryCarbon MonoxideCell SurvivalCell physiologyCellsClinicalClinical NursingClinical ResearchClinical TrialsComplexCyclic GMPDataDiabetes MellitusDoseEnrollmentEnsureEnvironmentExposure toFundingGoalsGrantHarvestHomologous TransplantationHumanHypoxiaImmuneInfusion proceduresInjuryInsulinInsulin-Dependent Diabetes MellitusIntractable PainIslet CellIslets of Langerhans TransplantationKidney TransplantationMethodsModelingNon-Insulin-Dependent Diabetes MellitusNutrientOperative Surgical ProceduresPancreasPancreatectomyPatientsPeroxisome Proliferator-Activated ReceptorsPhase II Clinical TrialsProceduresProtocols documentationQuality of lifeReactive Oxygen SpeciesResearchRestSolutionsStressSurgical ManagementTestingTimeTotal PancreatectomyTranslatingTransplantationUnited Statesbasebench to bedsidechronic pancreatitiscytokinedeprivationexperienceimplantationimprovedisletmeetingsnovelnovel strategiespreventpublic health relevanceresponsestressor
项目摘要
DESCRIPTION (provided by applicant): Total pancreatectomy and islet autotransplantation (IAT) is safe and effective in the management of intractable pain associated with chronic pancreatitis. A major problem associated with IAT is that the number of islets available for transplant is compromised by a severely diseased and fibrotic pancreas. Moreover, as many as 50-60% of islet cells undergo apoptosis at 2-3 days after intraportal transplantation when transplantation associated stressors (hypoxia, nutrient deprivation, reactive oxygen species, proinflammation cytokines) are induced during harvesting, isolation, and implantation of the islet cell mass. Although the quality-of-life parameters are significantly improved in our IAT patients, only 25% of patients become insulin independent (compared to 80% patients with normoglycemia before pancreatectomy). Strategies that produce more "robust" islets to resist stressors that induce ¿ cell apoptosis are an appealing and promising method to improve the efficiency of human IAT. Over the past 10 years we have focused on exploring strategies that can improve islet/¿ cell survival and function to treat patient with type-1 diabetes in the settingof allogeneic transplantation. Our novel findings indicate that exposing islets to low doses of carbon monoxide (CO, gaseous or dissolved in solutions) to the islet donor, or isolated islets, can protect those islets from stress-induced apoptosis and immune rejection after transplantation. Further study indicates that CO exposure to islet donor up-regulates expression of PPAR?, a transcriptional factor, in isolated islets. Donor treatment with PPAR? agonists leads to long-term (>100 days) survival of transplanted islets in a major mismatch islet transplantation
model without any additional treatments. Islet autografts suffer from similar injuries as allograft
and are spared the additional complexities of immune rejection response after transplantation. Thus, strategies such as PPAR? activation and CO exposure that can protect human islets from stress will bring immediate benefit to patients with chronic pancreatitis receiving an IAT and potentially serve as a platform on which to address the more complex allogeneic islet cell transplantation. In this study, we will test the hypothesis that stress-induced apoptosis of post IAT islets can be minimized leading to increased survival and function by harvesting islets in a CO-rich environment and/or PPAR? induction is isolated islets. Our state-of-the-art cGMP facility that undertakes IAT on a regular basis, our strong clinical and research team, clinical tral support, clinical trial nursing, clinical facilities, current patient pool and the biostatistics suport at MUSC offers powerful platform that can readily translate research finding from bench to bedside. Once the study is completed, it promises to advance the field of islet transplantation forward.
描述(由申请人提供):全胰腺切除术和胰岛自体移植(IAT)是治疗慢性胰腺炎相关难治性疼痛安全有效的方法。与IAT相关的一个主要问题是,可用于移植的胰岛数量受到严重病变和纤维化胰腺的损害。此外,当移植相关的应激源(缺氧、营养剥夺、活性氧、促炎症细胞因子)在胰岛细胞团的收获、分离和植入过程中被诱导时,多达50-60%的胰岛细胞在门静脉内移植后2-3天发生凋亡。尽管IAT患者的生活质量参数得到了显著改善,但只有25%的患者实现了胰岛素独立(相比之下,胰切除术前血糖正常的患者为80%)。产生更“健壮”的胰岛来抵抗诱导细胞凋亡的应激源的策略是提高人类IAT效率的一种有吸引力和有前途的方法。在过去的10年里,我们一直致力于探索能够改善胰岛细胞存活和功能的策略,以治疗异体移植的1型糖尿病患者。我们的新发现表明,将胰岛暴露于低剂量的一氧化碳(CO,气态或溶解在溶液中)给胰岛供体或分离的胰岛,可以保护这些胰岛在移植后免受应激诱导的细胞凋亡和免疫排斥。进一步研究表明,CO暴露于胰岛供体可上调PPAR?一种转录因子,存在于孤立的胰岛中。用PPAR治疗供体?在一个主要的错配胰岛移植中,激动剂可导致移植胰岛的长期(bb0 - 100天)存活
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hongjun Wang其他文献
Hongjun Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hongjun Wang', 18)}}的其他基金
Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Chronic Pancreatitis and Its Associated Pain
间充质干细胞治疗慢性胰腺炎及其相关疼痛的安全性和有效性
- 批准号:
10721284 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10474572 - 财政年份:2021
- 资助金额:
$ 22.43万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10315988 - 财政年份:2021
- 资助金额:
$ 22.43万 - 项目类别:
Autologous BM-MSCs and Islet Co-transplantation to Enhance Islet Survival and Function in TP-IAT Patients
自体 BM-MSC 和胰岛联合移植可增强 TP-IAT 患者的胰岛存活和功能
- 批准号:
10640946 - 财政年份:2021
- 资助金额:
$ 22.43万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10292900 - 财政年份:2019
- 资助金额:
$ 22.43万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10044402 - 财政年份:2019
- 资助金额:
$ 22.43万 - 项目类别:
hAAT-engineered Mesenchymal Stem Cells for the Treatment of Chronic Pain
hAAT 工程改造的间充质干细胞用于治疗慢性疼痛
- 批准号:
10515305 - 财政年份:2019
- 资助金额:
$ 22.43万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10599910 - 财政年份:2019
- 资助金额:
$ 22.43万 - 项目类别:
Cellular Therapy for Type 1 Diabetes using Mesenchymal Stem Cells
使用间充质干细胞进行 1 型糖尿病的细胞疗法
- 批准号:
10376342 - 财政年份:2019
- 资助金额:
$ 22.43万 - 项目类别:
Micro- and nanofiber enabled biomimetic periosteum for bone repair and reconstruction
微米和纳米纤维仿生骨膜用于骨修复和重建
- 批准号:
9026932 - 财政年份:2016
- 资助金额:
$ 22.43万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 22.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 22.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 22.43万 - 项目类别: